Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Haibao Pearl Mingmu eye drops (Zhenzhu Mingmu eye drops) is a traditional Chinese medicine (TCM) ophthalmic formulation developed and manufactured by Beihai Gofar Chuanshan Biological. It is primarily composed of pearl liquid (pearl extract/hydrolysate) and borneol. The formulation is indicated for the treatment of visual fatigue (asthenopia) and chronic conjunctivitis. Pearl liquid provides amino acids and trace elements that support ocular tissue repair and exhibit anti-inflammatory and anti-apoptotic properties, while borneol provides a cooling sensation, improves local microcirculation, and facilitates drug penetration through the corneal epithelium. It is administered topically as an ophthalmic solution.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zhenzhu mingmu eye drops.